News

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Financial Times

Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.